Literature DB >> 34490514

LRPs in WNT Signalling.

Gary Davidson1.   

Abstract

The WNT/β-catenin signalling pathway is a rich and complex network of cellular proteins that orchestrates diverse short-range cell-to-cell communication in metazoans and is essential for both embryonic development and adult homeostasis. Due to its fundamental importance in controlling cell behaviour at multiple levels, its deregulation is associated with a wide range of diseases in humans and identification of drugs targeting the pathway has attracted strong interest in the pharmaceutical sector. Transduction of WNT signals across the plasma membrane of cells involves a staggering degree of complexity and variety with respect to ligand-receptor, receptor-receptor and receptor-co-receptor interactions (Niehrs, Nat Rev Mol Cell Biol 13:767-779, 2012). Although the low-density-lipoprotein-receptor-related-protein (LRP) family is best known for its role in binding and endocytosis of lipoproteins, specific members appear to have additional roles in cellular communication. Indeed, for WNT/β-catenin signalling one apparently universal requirement is the presence of either LRP5 or LRP6 in combination with one of the ten Frizzled (FZD) WNT receptors (FZD1-10). In the 20 years since their discovery as WNT/FZD co-receptors, research on the LRP family has contributed greatly to our understanding of WNT signalling and LRPs have emerged as central players in WNT/β-catenin signalling. LRP5/6 are highly similar and represent the least redundant class of WNT receptor that transduce WNT/β-catenin signalling from a wide range of different WNT and FZD subtypes. This apparent simplicity however belies the complex arrangement of binding sites in the extracellular domain (ECD) of LRP5/6, which regulate interaction not only with WNTs but also with several inhibitors of WNT signalling. This chapter provides a historical overview, chronologically charting this remarkable progress in the field during the last 20 years of research on LRPs and their role in WNT/-catenin signalling. A more focused overview of the structural, functional and mechanistic aspects of LRP biology is also provided, together with the implications this has for pharmacological targeting of this notoriously intractable pathway.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  DKK therapeutic antibodies; LRP; LRP4; LRP5; LRP5 disease mutations; LRP6; LRP6 disease mutations; LRP6 structure; Sclerostin therapeutic antibodies; Wnt; Wnt co-receptor; Wnt surrogates

Mesh:

Substances:

Year:  2021        PMID: 34490514     DOI: 10.1007/164_2021_526

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  167 in total

1.  Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6.

Authors:  Victoria E Ahn; Matthew Ling-Hon Chu; Hee-Jung Choi; Denise Tran; Arie Abo; William I Weis
Journal:  Dev Cell       Date:  2011-10-13       Impact factor: 12.270

2.  Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow.

Authors:  A Bafico; G Liu; A Yaniv; A Gazit; S A Aaronson
Journal:  Nat Cell Biol       Date:  2001-07       Impact factor: 28.824

3.  Palmitoylation and ubiquitination regulate exit of the Wnt signaling protein LRP6 from the endoplasmic reticulum.

Authors:  Laurence Abrami; Béatrice Kunz; Ioan Iacovache; F Gisou van der Goot
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-31       Impact factor: 11.205

4.  A new member of the frizzled family from Drosophila functions as a Wingless receptor.

Authors:  P Bhanot; M Brink; C H Samos; J C Hsieh; Y Wang; J P Macke; D Andrew; J Nathans; R Nusse
Journal:  Nature       Date:  1996-07-18       Impact factor: 49.962

5.  Regulation of osteoblastogenesis and bone mass by Wnt10b.

Authors:  Christina N Bennett; Kenneth A Longo; Wendy S Wright; Larry J Suva; Timothy F Lane; Kurt D Hankenson; Ormond A MacDougald
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

6.  Mitotic wnt signaling promotes protein stabilization and regulates cell size.

Authors:  Sergio P Acebron; Emil Karaulanov; Birgit S Berger; Ya-Lin Huang; Christof Niehrs
Journal:  Mol Cell       Date:  2014-05-15       Impact factor: 17.970

7.  Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.

Authors:  Minrong Ai; Sheri L Holmen; Wim Van Hul; Bart O Williams; Matthew L Warman
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

Review 8.  β-Catenin-Independent Roles of Wnt/LRP6 Signaling.

Authors:  Sergio P Acebron; Christof Niehrs
Journal:  Trends Cell Biol       Date:  2016-08-24       Impact factor: 20.808

9.  LRP4 is critical for neuromuscular junction maintenance.

Authors:  Arnab Barik; Yisheng Lu; Anupama Sathyamurthy; Andrew Bowman; Chengyong Shen; Lei Li; Wen-cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2014-10-15       Impact factor: 6.167

10.  WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop.

Authors:  Megan J Agajanian; Matthew P Walker; Alison D Axtman; Roberta R Ruela-de-Sousa; D Stephen Serafin; Alex D Rabinowitz; David M Graham; Meagan B Ryan; Tigist Tamir; Yuko Nakamichi; Melissa V Gammons; James M Bennett; Rafael M Couñago; David H Drewry; Jonathan M Elkins; Carina Gileadi; Opher Gileadi; Paulo H Godoi; Nirav Kapadia; Susanne Müller; André S Santiago; Fiona J Sorrell; Carrow I Wells; Oleg Fedorov; Timothy M Willson; William J Zuercher; Michael B Major
Journal:  Cell Rep       Date:  2019-01-02       Impact factor: 9.423

View more
  1 in total

1.  Heterozygous LRP1 deficiency causes developmental dysplasia of the hip by impairing triradiate chondrocytes differentiation due to inhibition of autophagy.

Authors:  Wenjin Yan; Liming Zheng; Xingquan Xu; Zheng Hao; Yibo Zhang; Jun Lu; Ziying Sun; Jin Dai; Dongquan Shi; Baosheng Guo; Qing Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-06       Impact factor: 12.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.